Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel

Ann Intern Med. 2019 Jun 4;170(11):791-792. doi: 10.7326/M18-3513. Epub 2019 May 28.

Authors

Ali Duarte-García¹, Eric L Matteson¹, Nilay D Shah¹

Affiliation

¹ Mayo Clinic College of Medicine and Science, Rochester, Minnesota (A.D., E.L.M., N.D.S.).

PMID: 31060052
DOI: 10.7326/M18-3513

No abstract available

MeSH terms

Adrenocorticotropic Hormone / economics*
Adrenocorticotropic Hormone / therapeutic use*
Antirheumatic Agents / economics
Antirheumatic Agents / therapeutic use
Drug Approval
Drug Costs
Evidence-Based Medicine*
Humans
United States
United States Food and Drug Administration

Substances

Antirheumatic Agents
Adrenocorticotropic Hormone